3-hydroxy-3-[2',4'-difluorophenyl]-2-butanone | 436097-05-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-hydroxy-3-[2',4'-difluorophenyl]-2-butanone
• 英文别名: 3-(2,4-Difluorophenyl)-3-hydroxybutan-2-one
• CAS: 436097-05-1
• 化学式: C₁₀H₁₀F₂O₂
• 分子量: 200.185
• InChiKey: CCLGTNUNOSCZKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-hydroxy-3-[2',4'-difluorophenyl]-2-butanone 在 lithium hydroxide 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 5-(2,4-difluoro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid
  参考文献：
  名称：

  Analogues of Acifran:  Agonists of the High and Low Affinity Niacin Receptors, GPR109a and GPR109b

  摘要：

  Recently identified GPCRs, GPR109a and GPR109b, the high and low affinity receptors for niacin, may represent good targets for the development of HDL elevating drugs for the treatment of atherosclerosis. Acifran, an agonist of both receptors, has been tested in human subjects, yet until recently very few analogs had been reported. We describe a series of acifran analogs prepared using newly developed synthetic pathways and evaluated as agonists for GPR109a and GPR109b, resulting in identification of compounds with improved activity at these receptors.

  DOI：

  10.1021/jm070022x
• 作为产物：
  描述：

  2',4'-二氟苯乙酮 在 甲醇 、 正丁基锂 、 mercury(II) perchlorate 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 3-hydroxy-3-[2',4'-difluorophenyl]-2-butanone
  参考文献：
  名称：

  Analogues of Acifran:  Agonists of the High and Low Affinity Niacin Receptors, GPR109a and GPR109b

  摘要：

  Recently identified GPCRs, GPR109a and GPR109b, the high and low affinity receptors for niacin, may represent good targets for the development of HDL elevating drugs for the treatment of atherosclerosis. Acifran, an agonist of both receptors, has been tested in human subjects, yet until recently very few analogs had been reported. We describe a series of acifran analogs prepared using newly developed synthetic pathways and evaluated as agonists for GPR109a and GPR109b, resulting in identification of compounds with improved activity at these receptors.

  DOI：

  10.1021/jm070022x

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX
  申请人：Deng Huayun

  公开号：US20120022116A1

  公开（公告）日：2012-01-26

  Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject. The compounds having a formula (I), (II) or (III):

  揭示了与GPR35及/或GPR35-hERG信号复合物在病理生理上相关的疾病的预防和/或治疗的组合物和方法。例如，揭示了用于预防和/或治疗与GPR35在受试者中病理生理相关的疾病的化合物。这些化合物具有以下公式(I)、(II)或(III)：
• ELECTRO-OPTIC POLYMER
  申请人：NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY

  公开号：US20210032228A1

  公开（公告）日：2021-02-04

  The present invention provides an electro-optic polymer (EO polymer) comprising an electro-optic molecule (EO molecule) and a base polymer. The EO polymer of the present invention has good performance over the entire optical communication wavelength range and therefore can preferably be used for the production of optical modulators, optical switches, optical transceivers, optical phased arrays, LiDAR (light detection and ranging) devices, electric field sensors, terahertz wave generators and detectors, etc.

  本发明提供了一种电光聚合物（EO聚合物），包括电光分子（EO分子）和基础聚合物。本发明的EO聚合物在整个光通信波长范围内具有良好的性能，因此可以优选用于光调制器、光开关、光收发器、光子阵列、激光雷达（LiDAR）、电场传感器、太赫兹波发生器和探测器等的生产。
• MOLECULES RELATED hERG ION CHANNELS AND THE USE THEREOF
  申请人：Deng Huayun

  公开号：US20120329865A1

  公开（公告）日：2012-12-27

  Disclosed are compounds having structural formula (I, II) or a pharmaceutically acceptable sale, solvate, clathrate, or prodrug thereof, wherein R 1 , R 2 , R 3 , R 6 , R 5 , and R 4 are defined herein. These compounds can be useful as therapeutic agents for modulating hERG ion channels, and for improving prevention and treatment of hERG associated cardiac repolarization disorders.
• Analogues of Acifran:  Agonists of the High and Low Affinity Niacin Receptors, GPR109a and GPR109b
  作者：Jae-Kyu Jung、Benjamin R. Johnson、Tracy Duong、Marc Decaire、Jane Uy、Tawfik Gharbaoui、P. Douglas Boatman、Carleton R. Sage、Ruoping Chen、Jeremy G. Richman、Daniel T. Connolly、Graeme Semple

  DOI：10.1021/jm070022x

  日期：2007.4.1

  Recently identified GPCRs, GPR109a and GPR109b, the high and low affinity receptors for niacin, may represent good targets for the development of HDL elevating drugs for the treatment of atherosclerosis. Acifran, an agonist of both receptors, has been tested in human subjects, yet until recently very few analogs had been reported. We describe a series of acifran analogs prepared using newly developed synthetic pathways and evaluated as agonists for GPR109a and GPR109b, resulting in identification of compounds with improved activity at these receptors.